Invesaro

Stocks Health care LFWD

NASDAQ · Health care

Lifeward Ltd. (LFWD)

Lifeward Ltd. brought in $21.8M of revenue over the twelve months to June 30, 2026, down 10.7% from a year earlier. It posted a net loss of $30.8M. In fiscal 2025 capital spending exceeded operating cash flow by $16.8M. At June 30, 2026 it held $9.4M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 14, 2026.

Watch LFWD in 60 seconds
Price
$6.99
+0.29% on the day · September 25, 2026
52-week range $4.14 to $10.20
Market cap
$19.8M
Revenue (last 12 months)
$21.8M
-10.7% year on year
Net margin
-141.3%

What Lifeward Ltd. does

Lifeward Ltd. is registered with the SEC under industry code SIC 3842 (Orthopedic, Prosthetic & Surgical Appliances & Supplies). Its shares trade on NASDAQ under the ticker LFWD.

Revenue and profit by year

Revenue
FY18: $6.5M $6.5M FY18FY19: $4.9M $4.9M FY19FY20: $4.4M $4.4M FY20FY21: $6M $6M FY21FY22: $5.5M $5.5M FY22FY23: $13.9M $13.9M FY23FY24: $25.7M $25.7M FY24FY25: $22M $22M FY25
Net income
FY18: -$21.7M -$21.7M FY18FY19: -$15.6M -$15.6M FY19FY20: -$13M -$13M FY20FY21: -$12.7M -$12.7M FY21FY22: -$19.6M -$19.6M FY22FY23: -$22.1M -$22.1M FY23FY24: -$28.9M -$28.9M FY24FY25: -$19.9M -$19.9M FY25

Fiscal years as reported in annual reports. Amounts in USD.

Key figures

Fiscal yearRevenueOperating incomeNet incomeDiluted EPSFree cash flow
2025$22M-$19.7M-$19.9M-$17.16-$16.8M
2024$25.7M-$29.3M-$28.9M-$39.96-$21.7M
2023$13.9M-$23.6M-$22.1M-$31.13-$20.7M
2022$5.5M-$19.1M-$19.6M-$26.44-$17.9M
2021$6M-$12.7M-$12.7M-$23.03-$11.5M
2020$4.4M-$12M-$13M-$69.94-$12.7M

Full financial statements: income, balance sheet and cash flow

Next report expected around October 28, 2026.

Estimated from its filing rhythm: about 75 days after its last report of August 14, 2026, its usual gap. Not a date the company has announced. See the report calendar

Where LFWD ranks in Health care

Revenue$22M
#430 of 646 in Health care · Bottom 33%
Revenue growth-14.1%
#425 of 474 in Health care · Bottom 10%
Net margin-90.4%
#388 of 485 in Health care · Bottom 20%
Free cash flow margin-76.4%
#355 of 440 in Health care · Bottom 19%

Latest fiscal year of every company in the sector with the figure reported. Revenue is ranked among companies reporting in US dollars; growth and margins among companies with at least 10 million of revenue. Health care

Latest SEC filings

What Lifeward Ltd. has filed recently, newest first. Each links to the original document on SEC EDGAR.

  1. September 25, 2026
  2. September 25, 2026
  3. September 15, 2026
  4. September 15, 2026
  5. September 8, 2026
  6. August 31, 2026
  7. August 20, 2026
  8. August 14, 2026
    Quarterly report 10-Q · period to June 30, 2026Revenue rose 16% to $6.6M versus the same quarter last year; diluted EPS -$4.12 versus -$7.01.
  9. August 14, 2026
  10. August 3, 2026

Recent insider filings (Forms 3, 4 and 144): 9, the latest on September 10, 2026. Insider transactions on SEC

Insider trades

What the people running Lifeward Ltd. did with its shares, from the Form 4 filings they must send the SEC within two business days.

No insider bought or sold shares on the open market in the last 90 days. The 3 reported changes were pay in shares, option exercises, shares withheld for tax or gifts.

Bought (open market)
$0
last 90 days
Sold
$0
last 90 days
DateInsiderWhatSharesPriceValueFiling
August 20, 2026 Gabay AvrahamDirector Received as pay 13,643 - - Form 4
August 14, 2026 Zamir HaggaiDirector Received as pay 6,711 - - Form 4
August 14, 2026 Greenwald YonasonDirector Received as pay 6,711 - - Form 4
May 1, 2026 Rose Keith DaleChief Medical Officer Received as pay 15,000 - - Form 4

All insider filings on SEC.gov · Where insiders are buying across the market

Who owns LFWD

Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.

5% holders

Anyone who owns more than 5% of a class of shares must say so on Schedule 13D (if they may seek to influence the company) or 13G (a passive holder). The latest filing of each holder is shown: 13G filings of the last 2 years, 13D of the last 3.

No holder of 5% or more has filed about this company in that window.

Latest filings below 5%: Mitchell P. Kopin 4.99% (July 1, 2025); Lind Global Fund II LP 1.7% (May 15, 2025).

Largest institutional holders

No Form 13F positions imported for this company yet.

Insiders

Reported holdings of insiders who filed a Form 4 in the last 12 months: the shares each one held after their latest reported transaction. This is not the total held by all insiders.

4 insiders reported holding 44,148 shares in total, about $308.6K at the last price.

HolderSharesAs of
Rose Keith DaleChief Medical Officer 17,083 May 1, 2026
Gabay AvrahamDirector 13,643 August 20, 2026
Greenwald YonasonDirector 6,711 August 14, 2026
Zamir HaggaiDirector 6,711 August 14, 2026

Schedule 13D/13G filings on SEC.gov

All filings on SEC EDGAR

Questions about LFWD

What does Lifeward Ltd. do?

Lifeward Ltd. is registered with the SEC under industry code SIC 3842 (Orthopedic, Prosthetic & Surgical Appliances & Supplies). Its shares trade on NASDAQ under the ticker LFWD.

Is Lifeward Ltd. profitable?

No. Over the twelve months to June 30, 2026 it reported a net loss of $30.8M on revenue of $21.8M.

How much revenue does Lifeward Ltd. make?

Over the twelve months to June 30, 2026 Lifeward Ltd. reported revenue of $21.8M. That is 10.7% less than a year earlier.

When did Lifeward Ltd. last report?

Its most recent periodic report is the quarterly report (10-Q) filed on August 14, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the annual report to shareholders from September 25, 2026.

Similar companies

Compare LFWD with

Compare LFWD with any company

Follow LFWD

Get an email when Lifeward Ltd. files with the SEC: results, executive changes, material agreements and annual reports.

Follow LFWD: get an email when it files

Where the numbers come from

Financial figures are the values Lifeward Ltd. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.

Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.